Movement Alert｜Boston Scientific Intraday Rise 3.83% in Regular Trading, Blackstone Life Sciences Co-Funding Boosts Heart Pump Pipeline

Market Focus11-04 22:32

On November 4, Boston Scientific rose 3.83% in Regular Trading, trading at $45.88 per share, with turnover of $43.52 million.

The move followed news that Boston Scientific and Blackstone Life Sciences will co-fund development of the VITALYST temporary percutaneous transvalvular circulatory support system in a $455 million collaboration, lifting expectations for the company’s longer-term cardiovascular pipeline.

According to disclosed details, the device is intended for patients with cardiogenic shock and is designed to increase cardiac output and improve blood flow to the brain and other vital organs, while targeting better efficacy, safety and ease of use for physicians. The arrangement also marks the first time Blackstone Life Sciences and Boston Scientific have jointly funded development of a Boston Scientific product. The announcement helped offset recent pressure after Boston Scientific cut full-year adjusted EPS guidance to $3.16-$3.18 following a cybersecurity-related disruption, despite third-quarter revenue and adjusted EPS coming in slightly above expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118810343?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-04 22:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118810343","market":"us","top_or_hot":-1,"title":"Movement Alert｜Boston Scientific Intraday Rise 3.83% in Regular Trading, Blackstone Life Sciences Co-Funding Boosts Heart Pump Pipeline","media":"Market Focus","content":"<p><p>On November 4, Boston Scientific rose 3.83% in Regular Trading, trading at $45.88 per share, with turnover of $43.52 million.</p><p>The move followed news that Boston Scientific and Blackstone Life Sciences will co-fund development of the VITALYST temporary percutaneous transvalvular circulatory support system in a $455 million collaboration, lifting expectations for the company’s longer-term cardiovascular pipeline.</p><p>According to disclosed details, the device is intended for patients with cardiogenic shock and is designed to increase cardiac output and improve blood flow to the brain and other vital organs, while targeting better efficacy, safety and ease of use for physicians. The arrangement also marks the first time Blackstone Life Sciences and Boston Scientific have jointly funded development of a Boston Scientific product. The announcement helped offset recent pressure after Boston Scientific cut full-year adjusted EPS guidance to $3.16-$3.18 following a cybersecurity-related disruption, despite third-quarter revenue and adjusted EPS coming in slightly above expectations.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Boston Scientific Intraday Rise 3.83% in Regular Trading, Blackstone Life Sciences Co-Funding Boosts Heart Pump Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Boston Scientific Intraday Rise 3.83% in Regular Trading, Blackstone Life Sciences Co-Funding Boosts Heart Pump Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-11-04 22:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On November 4, Boston Scientific rose 3.83% in Regular Trading, trading at $45.88 per share, with turnover of $43.52 million.</p><p>The move followed news that Boston Scientific and Blackstone Life Sciences will co-fund development of the VITALYST temporary percutaneous transvalvular circulatory support system in a $455 million collaboration, lifting expectations for the company’s longer-term cardiovascular pipeline.</p><p>According to disclosed details, the device is intended for patients with cardiogenic shock and is designed to increase cardiac output and improve blood flow to the brain and other vital organs, while targeting better efficacy, safety and ease of use for physicians. The arrangement also marks the first time Blackstone Life Sciences and Boston Scientific have jointly funded development of a Boston Scientific product. The announcement helped offset recent pressure after Boston Scientific cut full-year adjusted EPS guidance to $3.16-$3.18 following a cybersecurity-related disruption, despite third-quarter revenue and adjusted EPS coming in slightly above expectations.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BSX","symbol_name":"波士顿科学","start_time":0,"source_url":"","article_id":"1118810343","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118810343","pubTimestamp":1793802734,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On November 4, Boston Scientific rose 3.83% in Regular Trading, trading at $45.88 per share, with turnover of $43.52 million.The move followed news that Boston Scientific and Blackstone Life Sciences...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BSX":"波士顿科学"},"translate_title":"走势提醒|波士顿科学常规交易盘中上涨3.83%，黑石生命科学联合融资推动心脏泵管道","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1},"content_text":"On November 4, Boston Scientific rose 3.83% in Regular Trading, trading at $45.88 per share, with turnover of $43.52 million.The move followed news that Boston Scientific and Blackstone Life Sciences will co-fund development of the VITALYST temporary percutaneous transvalvular circulatory support system in a $455 million collaboration, lifting expectations for the company’s longer-term cardiovascular pipeline.According to disclosed details, the device is intended for patients with cardiogenic shock and is designed to increase cardiac output and improve blood flow to the brain and other vital organs, while targeting better efficacy, safety and ease of use for physicians. The arrangement also marks the first time Blackstone Life Sciences and Boston Scientific have jointly funded development of a Boston Scientific product. The announcement helped offset recent pressure after Boston Scientific cut full-year adjusted EPS guidance to $3.16-$3.18 following a cybersecurity-related disruption, despite third-quarter revenue and adjusted EPS coming in slightly above expectations.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118810343","isCrawlerRequest":true}